Harriet Kluger, MD

Dr. Kluger is a medical oncologist who sees patients with melanoma and renal cell carcinoma. Her research interests focus on developing new drug regimens and biomarkers predictive of response to therapies in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs an active research laboratory that studies tumor and immune cells from patients treated with novel therapies to determine mechanisms of resistance to therapy and mediators of toxicity from immune checkpoint inhibitors. The laboratory also conducts pre-clinical studies to improve treatment regimens for patients with melanoma, renal cell carcinoma or brain metastasis.
Please visit the lab website at:
https://sites.google.com/yale.edu/hklugerlab/home?authuser=3

Education & Training:
Fellow-Yale University School of Medicine (2002)
Resident-University of New Mexico (1995)
MD-Tel Aviv University (1993)